Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 10/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | FNTA | P49354 | 1/20 | 0.39 |
| ▸ | FNTB | P49356 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.37 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1734450 | 0.92 | ALOX15 (0.45) | HDAC1HDAC6HDAC8ALOX15FNTA | |
| SCHEMBL3827595 | 0.87 | FNTA (0.46) | HDAC1HDAC6HDAC8ALOX15FNTA | |
| SCHEMBL12156914 | 0.85 | ALOX15 (0.43) | HDAC1HDAC6HDAC8ALOX15FNTA | |
| SCHEMBL1735369 | 0.82 | ROCK1 (0.42) | HDAC1HDAC6HDAC8FNTAFNTB | |
| SCHEMBL1736709 | 0.82 | HDAC1 (0.48) | HDAC1HDAC6ALOX15KDM4EKMT2A | |
| SCHEMBL1736704 | 0.82 | TAAR1 (0.56) | HDAC1HDAC6ALOX15FNTAFNTB | |
| SCHEMBL1734447 | 0.77 | ALOX15 (0.45) | HDAC1HDAC6ALOX15FNTAFNTB | |
| SCHEMBL1735400 | 0.77 | TRPV1 (0.47) | HDAC1HDAC6HDAC8ALOX15FNTA | |
| SCHEMBL1735373 | 0.77 | ALOX15 (0.45) | ALOX15FNTAFNTBTAAR1ALDH1A1 | |
| SCHEMBL3531066 | 0.75 | HDAC1 (0.46) | HDAC1HDAC6HDAC8ALOX15TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086959-B1 | SUBSTITUTED 2-IMIDAZOLES AS MODULATORS OF THE TRACE AMINE ASSOCIATED RECEPTORS | HOFFMANN LA ROCHE (CH) | 2011-11-16 | — | — | EP | claimed |
| US-20110264029-A1 | IONTOPHORETIC DELIVERY SYSTEM | Kopman, Stanley E. (CA) | 2011-10-27 | — | — | US | claimed |
| US-7834044-B2 | 1-(1H-imidazol-2-ylmethyl)-2,3-dihydro-1H-indole; good affinity to the trace amine associated receptors (TAARs), especially for TAAR1; psychotic disorders; neurodegenerative disorders; malfunction of body temperature homeostasis; cardiovascular disorders; depression, anxiety disorders, bipolar disorder | HOFFMAN-LAROCHE INC. (US) | 2010-11-16 | — | — | US | claimed |
| US-20080113980-A1 | 1-(1H-imidazol-2-ylmethyl)-2,3-dihydro-1H-indole; good affinity to the trace amine associated receptors (TAARs), especially for TAAR1; psychotic disorders; neurodegenerative disorders; malfunction of body temperature homeostasis; cardiovascular disorders; depression, anxiety disorders, bipolar disorder | HOFFMANN-LA ROCHE, INC. | 2008-05-15 | — | — | US | claimed |
| EP-2086959-B1 | SUBSTITUTED 2-IMIDAZOLES AS MODULATORS OF THE TRACE AMINE ASSOCIATED RECEPTORS | HOFFMANN LA ROCHE (CH) | 2011-11-16 | — | — | EP | disclosed |
| US-20110264029-A1 | IONTOPHORETIC DELIVERY SYSTEM | Kopman, Stanley E. (CA) | 2011-10-27 | — | — | US | disclosed |
| US-7834044-B2 | 1-(1H-imidazol-2-ylmethyl)-2,3-dihydro-1H-indole; good affinity to the trace amine associated receptors (TAARs), especially for TAAR1; psychotic disorders; neurodegenerative disorders; malfunction of body temperature homeostasis; cardiovascular disorders; depression, anxiety disorders, bipolar disorder | HOFFMAN-LAROCHE INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834044-B2 | 1-(1H-imidazol-2-ylmethyl)-2,3-dihydro-1H-indole; good affinity to the trace amine associated receptors (TAARs), especially for TAAR1; psychotic disorders; neurodegenerative disorders; malfunction of body temperature homeostasis; cardiovascular disorders; depression, anxiety disorders, bipolar disorder | HOFFMAN-LAROCHE INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834044-B2 | 1-(1H-imidazol-2-ylmethyl)-2,3-dihydro-1H-indole; good affinity to the trace amine associated receptors (TAARs), especially for TAAR1; psychotic disorders; neurodegenerative disorders; malfunction of body temperature homeostasis; cardiovascular disorders; depression, anxiety disorders, bipolar disorder | HOFFMAN-LAROCHE INC. (US) | 2010-11-16 | — | — | US | disclosed |
| EP-2086959-A1 | SUBSTITUTED 2-IMIDAZOLES AS MODULATORS OF THE TRACE AMINE ASSOCIATED RECEPTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-08-12 | — | — | EP | disclosed |
| US-20080113980-A1 | 1-(1H-imidazol-2-ylmethyl)-2,3-dihydro-1H-indole; good affinity to the trace amine associated receptors (TAARs), especially for TAAR1; psychotic disorders; neurodegenerative disorders; malfunction of body temperature homeostasis; cardiovascular disorders; depression, anxiety disorders, bipolar disorder | HOFFMANN-LA ROCHE, INC. | 2008-05-15 | — | — | US | disclosed |
| US-20080113980-A1 | 1-(1H-imidazol-2-ylmethyl)-2,3-dihydro-1H-indole; good affinity to the trace amine associated receptors (TAARs), especially for TAAR1; psychotic disorders; neurodegenerative disorders; malfunction of body temperature homeostasis; cardiovascular disorders; depression, anxiety disorders, bipolar disorder | HOFFMANN-LA ROCHE, INC. | 2008-05-15 | — | — | US | disclosed |
| US-20080113980-A1 | 1-(1H-imidazol-2-ylmethyl)-2,3-dihydro-1H-indole; good affinity to the trace amine associated receptors (TAARs), especially for TAAR1; psychotic disorders; neurodegenerative disorders; malfunction of body temperature homeostasis; cardiovascular disorders; depression, anxiety disorders, bipolar disorder | HOFFMANN-LA ROCHE, INC. | 2008-05-15 | — | — | US | disclosed |
| WO-2008052907-A1 | SUBSTITUTED 2-IMIDAZOLES AS MODULATORS OF THE TRACE AMINE ASSOCIATED RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008052907-A1 | SUBSTITUTED 2-IMIDAZOLES AS MODULATORS OF THE TRACE AMINE ASSOCIATED RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113980-A1 | 1-(1H-imidazol-2-ylmethyl)-2,3-dihydro-1H-indole; good affinity to the trace amine associated receptors (TAARs), especially for TAAR1; psychotic disorders; neurodegenerative disorders; malfunction of body temperature homeostasis; cardiovascular disorders; depression, anxiety disorders, bipolar disorder | TAAR1, TAAR5, MCHR1 | HDAC1 2190/4885HDAC6 2063/4885HDAC8 2705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.